BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-04

Study Completion Date

2021-04-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events. Secondary objectives are the collection of overall safety and antitumour efficacy data and the determination of the pharmacokinetic profile of BI 6727.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose Finding Study of BI 836880 in Patients With Solid Tumors

NCT02674152

Neoplasms

COMPLETED PHASE1

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

NCT01206816

Neoplasms

COMPLETED PHASE1

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit

NCT02211872

Neoplasms

COMPLETED PHASE1

A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps

NCT07224425

Solid Tumours Melanoma

NOT_YET_RECRUITING PHASE1

BI 811283 in Various Solid Tumours

NCT00701324

Neoplasms

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

12 mg BI 6727

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

24 mg BI 6727

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

48 mg BI 6727

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

75 mg BI 6727

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

125 mg BI 6727

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

200 mg BI 6727

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

300 mg BI 6727

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

300 mg BI 6727 1h2h

Infusion over 1 hour (1h) in course 1 and over 2 hours (2h) in course 2.

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

300 mg BI 6727 2h1h

Infusion over 2 hours (2h) in course 1 and over 1 hours (1h) in course 2.

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

350 mg BI 6727

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

400 mg BI 6727

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

450 mg BI 6727

Group Type EXPERIMENTAL

BI 6727

Intervention Type DRUG

BI 6727

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 6727

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Volasertib

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment
2. Age 18 years or older
3. Written informed consent consistent with ICH-GCP and local legislation
4. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ¿ 2
5. Recovery from CTCAE Grade 2 - 4 therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies (except alopecia)

The 18 additional patients recruited at the MTD must also meet the following criterion:
6. Measurable tumour deposits (RECIST) by one or more techniques (CT, MRI)

Exclusion Criteria

1. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
2. Pregnancy or breastfeeding
3. Active infectious disease or known chronic Hepatitis B/Hepatitis C infection
4. Clinical evidence of active brain or leptomeningeal disease during the past 12 months
5. Second malignancy currently requiring active therapy
6. Absolute neutrophil count less than 1500 / mm3
7. Platelet count less than 100 000 / mm3
8. Bilirubin greater than 1.5 mg / dl (\> 26 ¿mol / L, SI unit equivalent)
9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
10. Serum creatinine greater than 1.5 mg / dl (\> 132 ¿mol / L, SI unit equivalent)
11. Known history of relevant QT-prolongation, e.g. long QT-syndrome
12. Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
13. Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
14. Chemo-, radio or immunotherapy within the past four weeks before start of therapy or concomitantly with this trial. This restriction does not apply to steroids and bisphosphonates.
15. Patients unable to comply with the protocol
16. Active alcohol or drug abuse

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No